Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06GFV
|
|||
| Former ID |
DNC011525
|
|||
| Drug Name |
1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine
|
|||
| Synonyms |
CHEMBL31171; 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine; 1H-Indole-5-ethanamine, alpha-ethyl-2,3-dihydro-; BDBM50025077
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H18N2
|
|||
| Canonical SMILES |
CCC(CC1=CC2=C(C=C1)NCC2)N
|
|||
| InChI |
1S/C12H18N2/c1-2-11(13)8-9-3-4-12-10(7-9)5-6-14-12/h3-4,7,11,14H,2,5-6,8,13H2,1H3
|
|||
| InChIKey |
WHXRWSJORCUAFO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine transporter (DAT) | Target Info | Inhibitor | [1] |
| Norepinephrine transporter (NET) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Dopaminergic synapse | |||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Parkinson disease | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Dopaminergic Neurogenesis | ||||
| Parkinsons Disease Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Neurotransmitter Clearance In The Synaptic Cleft | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.